GlassScriptPhysician profile
Leslie K Archer
NPI 1033194436
$9,169.31
in general payments reported to CMS, 2019-2025
29 companies · $1,667 in 2025
The $1,667 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,411 · 2022: $1,777 · 2023: $2,429 · 2024: $1,886 · 2025: $1,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,973 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,972.51 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,868.44 | 2021-2025 | Injectafer |
| Novo Nordisk INC | $1,429.29 | 2021-2025 | Wegovy, Ozempic, Saxenda |
| Glaxosmithkline, LLC. | $1,381.23 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $990.91 | 2021-2025 | |
| Amgen INC. | $647.59 | 2021-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $609.59 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $346.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $303.23 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $267.22 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $204.50 | 2021-2025 | Farxiga, Breztri |
| Teva Pharmaceuticals USA, INC. | $180.84 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $166.46 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $132.20 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $127.43 | 2023-2025 | Auvelity, Symbravo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.19 | 2021-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $65.43 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $59.05 | 2021 | |
| Janssen Pharmaceuticals, INC | $41.61 | 2024 | Spravato |
| Antares Pharma, INC. | $38.24 | 2022 | |
| Astellas Pharma US INC | $34.52 | 2023 | Veozah |
| Sanofi Pasteur INC. | $24.31 | 2021 | |
| Dexcom, INC. | $23.29 | 2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $22.29 | 2025 | Rexulti |
| Seqirus USA INC | $20.89 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Heartflow, INC. | $17.39 | 2024 | |
| Avanir Pharmaceuticals, INC. | $17.31 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.52 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $13.76 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Archer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.